~~<i id='885DB2DCD9'><strike id='885DB2DCD9'><tt id='885DB2DCD9'><pre id='885DB2DCD9'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：focus 2025-09-28 04:06:17 Page View：424

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bristol 'take
Next article： The cancer drug shortage isn’t new — and neither are the solutions

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Phenylephrine and the overlooked value of the placebo effect

PATRICKT.FALLON/AFPviaGettyImagesAsthetemperaturescool,theseasonofcolds,flu,andnowCovid-19isheatingu

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

A Q&A with the global head of Boehringer Ingelheim's innovation unit

MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

WSS

knowledge

knowledge

comprehensive

leisure time

A Q&A with the global head of Boehringer Ingelheim's innovation unit